Thomas, Craig J.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,609

Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the Warburg effect in LPS-activated macrophages

Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A. R., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. M., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G. W., et al. (2015) · Cell Metabolism

Immune cells in cancerCancer, Hypoxia, and Metabolism

Cited by 1,397

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,260

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 816

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine

Genomics, phytochemicals, and oxidative stressLung Cancer Treatments and Mutations

Cited by 652

Increased demand for NAD(+) relative to ATP drives aerobic glycolysis

Luengo, A., Li, Z., Gui, D. Y., Sullivan, L. B., Zagorulya, M., Do, B. T., Ferreira, R., Naamati, A., Ali, A., Lewis, C. A., et al. (2021) · Molecular Cell

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 547

Environment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metformin

Gui, D. Y., Sullivan, L. B., Luengo, A., Hosios, A. M., Bush, L. N., Gitego, N., Davidson, S. M., Freinkman, E., Thomas, C. J., & Vander Heiden, M. G. (2016) · Cell Metabolism

Metabolism, Diabetes, and CancerCancer, Hypoxia, and Metabolism

Cited by 323

Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability

Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 271

Caspase-1 causes truncation and aggregation of the Parkinson’s disease-associated protein α-synuclein

Wang, W., Nguyen, L. T. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., Ju, S., Fisher, O. S., Miller, D. W., Datta, D., et al. (2016) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 270

Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer

Sayin, V. I., LeBoeuf, S. E., Singh, S. X., Davidson, S. M., Biancur, D., Guzelhan, B. S., Alvarez, S. W., Wu, W. L., Karakousi, T. R., Zavitsanou, A. M., et al. (2017) · eLife

Genomics, phytochemicals, and oxidative stressCancer, Hypoxia, and Metabolism

Cited by 231

Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome

Rhyasen, G. W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., et al. (2013) · Cancer Cell

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 199

Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function

Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 158

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions

Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 152

Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy

Law, A. J., Wang, Y., Sei, Y., O’Donnell, P., Piantadosi, P., Papaleo, F., Straub, R. E., Huang, W., Thomas, C. J., Vakkalanka, R., et al. (2012) · Proceedings of the National Academy of Sciences

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 147

O-GlcNAc regulates gene expression by controlling detained intron splicing

Tan, Z.-W., Fei, G., Paulo, J. A., Bellaousov, S., Martin, S. E. S., Duveau, D. Y., Thomas, C. J., Gygi, S. P., Boutz, P. L., & Walker, S. (2020) · Nucleic Acids Research

RNA Research and SplicingGlycosylation and Glycoproteins Research

Cited by 119

O-GlcNAc regulates gene expression by controlling detained intron splicing

Tan, Z.-W., Fei, G., Paulo, J. A., Bellaousov, S., Martin, S. E. S., Duveau, D. Y., Thomas, C. J., Gygi, S. P., Boutz, P. L., & Walker, S. (2020) · Nucleic Acids Research

RNA Research and SplicingGlycosylation and Glycoproteins Research

Cited by 119

eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma

Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 106

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites

Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses

Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 82

Synthesis, Activity, and Structural Analysis of Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H

Chung, S., Himmel, D. M., Jiang, J.-K., Wojtak, K., Bauman, J. D., Rausch, J. W., Wilson, J. A., Beutler, J. A., Thomas, C. J., Arnold, E., et al. (2011) · Journal of Medicinal Chemistry

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 80

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R )-hydroxynorketamine

Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology

Treatment of Major DepressionPharmacogenetics and Drug Metabolism

Cited by 62

Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma

Yang, Y., Bolomsky, A., Oellerich, T., Chen, P., Ceribelli, M., Häupl, B., Wright, G. W., Phelan, J. D., Huang, D. W., Lord, J. W., et al. (2022) · Nature Communications

PI3K/AKT/mTOR signaling in cancerMultiple Myeloma Research and Treatments

Cited by 29